Catatonia or no catatonia: still beyond lorazepam/amobarbital. 2007

Yatan Balhara

UI MeSH Term Description Entries
D008140 Lorazepam A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. Apo-Lorazepam,Ativan,Donix,Duralozam,Durazolam,Idalprem,Laubeel,Lorazep Von Ct,Lorazepam Medical,Lorazepam-Neuraxpharm,Lorazepam-Ratiopharm,Novo-Lorazem,Nu-Loraz,Orfidal Wyeth,Sedicepan,Sinestron,Somagerol,Temesta,Tolid,Témesta,WY-4036,Apo Lorazepam,Lorazepam Neuraxpharm,Lorazepam Ratiopharm,Medical, Lorazepam,Novo Lorazem,Nu Loraz,Von Ct, Lorazep,WY 4036,WY4036,Wyeth, Orfidal
D002389 Catatonia A neuropsychiatric disorder characterized by one or more of the following essential features: immobility, mutism, negativism (active or passive refusal to follow commands), mannerisms, stereotypies, posturing, grimacing, excitement, echolalia, echopraxia, muscular rigidity, and stupor; sometimes punctuated by sudden violent outbursts, panic, or hallucinations. This condition may be associated with psychiatric illnesses (e.g., SCHIZOPHRENIA; MOOD DISORDERS) or organic disorders (NEUROLEPTIC MALIGNANT SYNDROME; ENCEPHALITIS, etc.). (From DSM-IV, 4th ed, 1994; APA, Thesaurus of Psychological Index Terms, 1994) Catatonia, Malignant,Catatonia, Organic,Lethal Catatonia,Organic Catatonic Disorder,Schizophreniform Catatonia,Catatonia, Lethal,Catatonia, Schizophreniform,Catatonias,Catatonias, Lethal,Catatonias, Malignant,Catatonias, Organic,Catatonias, Schizophreniform,Catatonic Disorder, Organic,Catatonic Disorders, Organic,Lethal Catatonias,Malignant Catatonia,Malignant Catatonias,Organic Catatonia,Organic Catatonias,Organic Catatonic Disorders,Schizophreniform Catatonias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000654 Amobarbital A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) Amylobarbitone,Pentymal,Amobarbital Sodium,Amsal,Amylbarb sodium,Amylobeta,Amytal,Amytal Sodium,Barbamyl,Eunoctal,Isoamitil Sedante,Isonal,Neur-Amyl,Novamobarb,Placidel,Sodium Amobarbital,Sodium Amytal,Transital,Amobarbital, Sodium,Sodium, Amobarbital
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Yatan Balhara
April 1991, The Journal of clinical psychiatry,
Yatan Balhara
May 2012, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
Yatan Balhara
August 1987, The American journal of psychiatry,
Yatan Balhara
January 2023, Indian journal of psychological medicine,
Yatan Balhara
December 1979, Biological psychiatry,
Yatan Balhara
March 1996, Convulsive therapy,
Yatan Balhara
October 1987, Journal of clinical psychopharmacology,
Yatan Balhara
January 1993, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines,
Yatan Balhara
June 1988, The American journal of psychiatry,
Yatan Balhara
January 1997, Psychosomatics,
Copied contents to your clipboard!